BioCryst Pharmaceuticals
BCRX
241 hedge funds and large institutions have $1.42B invested in BioCryst Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 94 increasing their positions, 69 reducing their positions, and 24 closing their positions.
167% more call options, than puts
Call options by funds: $25.4M | Put options by funds: $9.49M
63% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 24
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
36% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 69
6.19% more ownership
Funds ownership: 84.17% → 90.36% (+6.2%)
5% more funds holding
Funds holding: 230 → 241 (+11)
31% less capital invested
Capital invested by funds: $2.07B → $1.42B (-$650M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$42.6M |
| 2 |
EP
Eversept Partners
New York
|
+$35M |
| 3 |
DM
Deerfield Management
New York
|
+$26.6M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$25.3M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$22.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$38.1M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$29.2M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$24.2M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$19M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18.6M |
BCRX Hedge Fund Activity: Q1 2023 in Review
241 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2023, worth a combined $1.42B — down 31% from $2.07B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new BCRX positions and 24 closed out — a net gain of 15 holders — while 94 added to existing stakes and 69 trimmed.
The largest buyer was Millennium Management, adding an estimated $42.6M. The largest seller was Fidelity Investments, cutting an estimated $38.1M.
- 241 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2023, up from 230 in Q4 2022.
- Funds reported $1.42B of BioCryst Pharmaceuticals stock for Q1 2023, down 31% quarter-over-quarter.
- 39 funds opened new BioCryst Pharmaceuticals positions in Q1 2023 and 24 closed out, a net change of +15 holders.
- The largest BioCryst Pharmaceuticals buyer in Q1 2023 was Millennium Management, an estimated $42.6M added.
- The largest BioCryst Pharmaceuticals seller in Q1 2023 was Fidelity Investments, an estimated $38.1M sold.
Based on aggregated 13F filings for Q1 2023.